Achilles Therapeutics (ACHL)
NASDAQ: ACHL
· Real-Time Price · USD
1.48
0.00 (0.00%)
At close: Mar 20, 2025, 3:59 PM
Achilles Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 1.18M | 1.18M | 1.16M | 1.2M | 1.3M | n/a | 837.23K | 892.33K | 892.17K | 1.05M | 838.03K | 895.96K | 798.44K | n/a |
Gross Profit | n/a | -1.18M | -1.18M | -1.16M | -1.2M | -1.3M | n/a | -837.23K | -892.33K | -892.17K | -1.05M | -838.03K | -895.96K | -798.44K | n/a |
Operating Income | -20.42M | -17.8M | -14.29M | -19.68M | -19.1M | -18.09M | -18.55M | -22.83M | -16.03M | -20.55M | -18.97M | -18.46M | -15.74M | -16.29M | -13.71M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -19.6M | -16.37M | -12.29M | -18.28M | -16.71M | -16.88M | -17.46M | -24.02M | -12.44M | -17.27M | -17.34M | -18.23M | -12.93M | -16.14M | -13.75M |
Net Income | -19.59M | -16.38M | -12.27M | -18.79M | -16.68M | -16.85M | -17.51M | -24.06M | -12.48M | -17.29M | -17.36M | -18.23M | -12.95M | -16.16M | -13.77M |
Selling & General & Admin | 4.02M | 4.16M | 2.98M | 2.5M | 4.38M | 4.32M | 4.68M | 3.96M | 5.44M | 5.77M | 5.96M | 6.65M | 5.04M | 5.45M | 4.83M |
Research & Development | 16.4M | 13.63M | 10.13M | 16.03M | 14.71M | 13.77M | 13.87M | 18.88M | 10.6M | 14.78M | 13.01M | 11.81M | 10.7M | 10.84M | 8.88M |
Other Expenses | n/a | n/a | n/a | n/a | 2.39M | 1.21M | n/a | -1.18M | 3.6M | 3.27M | 1.63M | 226K | 2.81M | 146K | -45K |
Operating Expenses | 20.42M | 17.8M | 13.11M | 18.53M | 19.1M | 18.09M | 18.55M | 22.83M | 16.03M | 20.55M | 18.97M | 18.46M | 15.74M | 16.29M | 13.71M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.18M | n/a | n/a | n/a | n/a | n/a | n/a | 45K |
Selling & Marketing Expenses | n/a | n/a | -1.18M | -1.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 20.42M | 17.8M | 14.29M | 19.68M | 19.1M | 18.09M | 18.55M | 22.83M | 16.03M | 20.55M | 18.97M | 18.46M | 15.74M | 16.29M | 13.71M |
Income Tax Expense | -5K | 8K | -22.99K | 509.39K | -24K | -34K | 44K | 41K | 41K | 14K | 15K | -4K | 16K | 13K | 12K |
Shares Outstanding (Basic) | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.9M | 39.73M | 39.52M | 39.31M | 39.1M | 38.89M | 28.65M | 38.26M | 35.68M | 38.15M |
Shares Outstanding (Diluted) | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M | 39.9M | 39.73M | 39.52M | 39.31M | 39.1M | 38.89M | 28.65M | 38.26M | 35.68M | 38.15M |
EPS (Basic) | -0.48 | -0.41 | -0.3 | -0.47 | -0.42 | -0.42 | -0.44 | -0.61 | -0.32 | -0.44 | -0.45 | -0.64 | -0.34 | -0.45 | -0.36 |
EPS (Diluted) | -0.48 | -0.41 | -0.3 | -0.47 | -0.42 | -0.42 | -0.44 | -0.61 | -0.32 | -0.44 | -0.45 | -0.64 | -0.34 | -0.45 | -0.36 |
EBITDA | -20.42M | -16.62M | -13.12M | -18.27M | -17.89M | -16.84M | -17.45M | -23.36M | -15.14M | -19.63M | -17.92M | -17.85M | -14.91M | -15.46M | -12.92M |
EBIT | -20.42M | -17.8M | -14.3M | -19.51M | -19.1M | -18.09M | -18.55M | -24.19M | -16.03M | -20.55M | -18.97M | -18.46M | -15.74M | -16.29M | -13.71M |
Depreciation & Amortization | n/a | 1.18M | 1.18M | 1.16M | 1.2M | 1.3M | 1.11M | 837.23K | 892.33K | 892.17K | 1.05M | 838.03K | 895.96K | 798.44K | 789K |